Utilizing OMICS, RWE, and AI: on the way to personalized medicine

---

作者

Amélie Zacharie¹ , Marion Mueller²

1. University of Freiburg
2. Novartis

会议/活动

Regulatory Affairs and Drug Development Master submission, May 2024, May 2024 (虚拟会议)

海报摘要

This poster highlights the utilization of OMICS, RWE, and AI in personalized medicine, showcasing their potential to improve therapeutic response, reduce adverse reactions, and enable proactive interventions, ultimately enhancing patient outcomes and overall quality of life.

关键词

OMICS, Real-world evidence, Artificial intelligence, Personalized medicine, Precision medicine

研究领域

Pharmacy and Pharmacology

参考文献

1. Bell, J. Predicting disease using genomics. Nature 429, 453–456 (2004). https://doi.org/10.1038/nature02624
2. Agarwala V, Khozin S, Singal G, et al. Real-World Evidence In Support Of Precision Medicine: Clinico Genomic Cancer Data As A Case Study. Health Affairs (Project Hope). 2018 May;37(5):765-772. doi: 10.1377/hlthaff.2017.1579.
3. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. doi:10.1038/s41591-018-0300-7.

基金

暂无数据

补充材料

暂无数据

附加信息

利益冲突

Marion Mueller is a full-time employee of Novartis Pharma AG and contributor to IMI ConcePTION, which is a public-private consortium funded by the European Government and the European Federation of Pharmaceutical Industry Associations. Amélie Zacharie has no competing interests.

数据可用性声明

Data sharing not applicable to this poster as no datasets were generated or analyzed during the current study.

知识共享许可协议

Copyright © 2024 Zacharie et al. This is an open access work distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.